MDS PANEL BY FISH (O.S)

Overview

Myelodysplastic syndrome (MDS) describes a group of clonal hematopoietic disorders resulting in ineffective production of one or more of the myeloid cell lineages which increases the risk by 35-40% for transformation to Acute Myeloid Leukemia (AML). More than 50% of patients with MDS have clonal cytogenetic abnormalities and these can be classified into 3 risk groups. Good prognosis: Deletion in the long arm of chromosome 5 & 20 is seen in 30% cases & prognosis is favorable; Intermediate risk: Trisomy 8 is associated with mean survival of 23 to 26 months; Poor risk: Monosomy 7 & complex chromosomal abnormalities is associated with median survival of <1 year.